Cited by 83Viral Infections and Immunology ResearchSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

IL-1RA Antibodies in Myocarditis after SARS-CoV-2 Vaccination

Open access
Thurner, Lorenz, Kessel, Christoph, Fadle, Natalie, Regitz, Evi, Seidel, Franziska, Kindermann, Ingrid, Lohse, Stefan, Kos, Igor +48 more·2022·New England Journal of Medicine

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmc2205667

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Most studies of COVID-19 report a male dominance of around 60% men to 40% women.

    “Most studies of COVID-19 report a male dominance of around 60% men to 40% women. 12,13”

    From COVID-19, Myocarditis and Pericarditis (2023) · cites this paper as [12]

    The opening paragraph (page not specified) says that myocarditis after SARS-CoV-2 mRNA vaccination predominantly affects male adolescents and young adults. It does not say that most studies of COVID-19 find a male predominance, or report a 60%–40% split; the claim extends a narrower observation to a different population. (LLM, conf=0.83)

    Experimental — accuracy not yet measured
  • Patients with elevated IL-1RA antibodies had higher levels of cardiac inflammation, CRP, and troponin.

    “They found that patients with elevated IL-1RA antibodies had higher levels of cardiac inflammation, CRP, and troponin. 12”

    From COVID-19, Myocarditis and Pericarditis (2023) · cites this paper as [12]

    In the section “IL-1RA Antibodies in Myocarditis after SARS-CoV-2 Vaccination” (page not specified), the paper links IL-1RA plasma levels to troponin, cardiac-tissue inflammatory-cell infiltration, and CRP, and reports cardiac damage and inflammation in patients with anti–IL-1RA antibodies. It does not show that patients with elevated antibody levels had higher levels of those markers than patients without the antibodies; its reported negative correlation concerns IL-1RA plasma levels, not antibody levels. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • COVID-19 occurs predominantly in men, which may be explained at least in part by a higher expression of ACE2 on male versus female cells.

    “COVID-19 occurs predominantly in men, 11-13 which may be explained, at least in part, by a higher expression of ACE2 on male versus female cells.”

    From COVID-19, Myocarditis and Pericarditis (2023) · cites this paper as [12]

    In the opening paragraph of the letter (page unavailable), the source says myocarditis after SARS-CoV-2 mRNA vaccination predominantly affects male adolescents and young adults. That is a different condition from COVID-19 itself, so it does not establish the cited claim that COVID-19 occurs predominantly in men. The source also does not discuss male–female differences in ACE2 expression. (LLM, conf=0.81)

    Experimental — accuracy not yet measured
  • Patients with biopsy-confirmed myocarditis following COVID-19 vaccination had elevated levels of antibodies directed against IL-1RA, which is part of the TLR4/IL-1R signaling family.

    “Thurner et al 12 found that patients with biopsy-confirmed myocarditis following COVID-19 vaccination had elevated levels of antibodies directed against IL-1RA, which is part of the TLR4/IL-1R signaling family.”

    From COVID-19, Myocarditis and Pericarditis (2023) · cites this paper as [12]

    The paper reports anti–IL-1RA antibodies in a subset of patients with biopsy-confirmed myocarditis after SARS-CoV-2 vaccination: 9 of 12 patients younger than 21 and 3 of 28 older patients. It describes IL-1RA as an inhibitor of interleukin-1 signaling, but does not identify it as part of a TLR4/IL-1R signaling family. The claim also omits that the antibodies were found in only a subset of these patients. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [3]3. Thurner L, Fadle N, Bewarder M, et al. Autoantibodies against progranulin and IL-1 receptor antagonist in critically ill COVID-19. April 26, 2021. (https://www.biorxiv.org/content/10.1101/2021.04.23.441188v1). preprint. · DOI

Cited by

Sorted by citations

Authors
Thurner, L., Kessel, C., Fadle, N., Regitz, E., Seidel, F., Kindermann, I., Lohse, S., Kos, I., Tschöpe, C., Kheiroddin, P., Kiblboeck, D., Hoffmann, M.-C., Bette, B., Carbon, G., Cetin, O., Preuss, K.-D., Christofyllakis, K., Bittenbring, J. T., Pickardt, T., Fischer, Y., Thiele, H., Baldus, S., Stangl, K., Steiner, S., Gietzen, F., Kerber, S., Deneke, T., Jellinghaus, S., Linke, A., Ibrahim, K., Grabmaier, U., Massberg, S., Thilo, C., Greulich, S., Gawaz, M., Mayatepek, E., Meyer-Dobkowitz, L., Kindermann, M., Birk, E., Birk, M., Lainscak, M., Foell, D., Lepper, P. M., Bals, R., Krawczyk, M., Mevorach, D., Hasin, T., Keren, A., Kabesch, M., Abdul-Khaliq, H., Smola, S., Bewarder, M., Thurner, B., Böhm, M., Pfeifer, J., & Klingel, K.
Affiliations
  • Saarland University (DE)
  • University of Münster (DE)
  • Deutsches Herzzentrum der Charité (DE)
  • Charité – Universitätsmedizin Berlin (DE)
  • University Hospital Regensburg (DE)
  • Johannes Kepler University of Linz (AT)
  • Competence Network for Congenital Heart Defects (DE)
  • RWTH Aachen University (DE)
  • Heart Center Leipzig, Leipzig, Germany
  • University Hospital Cologne (DE)
  • St. Vincenz-Krankenhaus Limburg (DE)
  • Cardiovascular Center Bad Neustadt–Saale, Bad Neustadt–Saale, Germany
  • Technische Universität Dresden (DE)
  • Klinikum Chemnitz (DE)
  • Ludwig-Maximilians-Universität München (DE)
  • RoMed Kliniken (DE)
  • University of Tübingen (DE)
  • Düsseldorf University Hospital (DE)
  • Klinikum Westbrandenburg, Potsdam, Germany
  • cts CaritasKlinikum Saarbrücken (DE)
  • Schneider Children's Medical Center (IL)
  • University of Ljubljana, Ljubljana, Slovenia
  • Hadassah Medical Center (IL)
  • Shaare Zedek Medical Center (IL)
  • Saarland University, Homburg, Germany
  • Klinikum Kempten, Kempten, Germany
  • Universitätsklinikum Tübingen (DE)
Corresponding author
Thurner, Lorenz
Venue
New England Journal of Medicine
Published
2022-10-20
Volume
387
Issue
16
Pages
1524-1527
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4296701731
Cited by
83
References
3
Citations by year
2026: 10 · 2025: 12 · 2024: 22 · 2023: 36 · 2022: 3
FWCI
12.71
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • University of Saarland (BioNanoMed Young Investigator)
  • Deutsche Herzstiftung
  • Land Baden-Württemberg (COVID-19 Projektförderung)
  • German Competence Network for Congenital Heart Defects (01GI0601)
  • National Register for Congenital Heart Defects (01KX2140)
  • State of Saarland (Funding of SaarCoVac registry)
  • Dr. Rolf M. Schwiete Stiftung
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Viral Infections and Immunology Research
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Keywords
interleukin-1 receptor antagonist, myocarditis, COVID-19 vaccination, COVID-19 vaccine adverse events, autoantibodies
MeSH terms
COVID-19, SARS-CoV-2, COVID-19 Vaccines, Antibodies, Humans, Myocarditis, Vaccination, Interleukin 1 Receptor Antagonist Protein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review